Radioactive brain cancer treatment enters human testing
NCT ID NCT05450744
Summary
This early-stage study is testing the safety of a radioactive drug called 131I-TLX101 when added to standard treatment for newly diagnosed glioblastoma, an aggressive brain cancer. Researchers will give increasing doses to 12 patients who have recently had surgery but haven't started other treatments yet. The main goal is to find the highest dose that patients can tolerate without severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gold Coast University Hospital
RECRUITINGGold Coast, Queensland, 4215, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut für Nuklearmedizin und Endokrinologie
RECRUITINGLinz, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Olivia Newton John Cancer Research Institute/Austin Health
RECRUITINGMelbourne, Victoria, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Adelaide Hospital
RECRUITINGAdelaide, South Australia, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal North Shore Hospital
RECRUITINGSydney, New South Wales, 2065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UNMC Utrecht
RECRUITINGUtrecht, 3051, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.